Seven‐year discordance in age at onset in monozygotic twins with inherited prion disease (P102L)

Abstract

Neuropathology and Applied NeurobiologyVolume 35, Issue 4 p. 427-432 Seven-year discordance in age at onset in monozygotic twins with inherited prion disease (P102L) T. Webb, T. Webb National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Mead, S. Mead National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorJ. Beck, J. Beck MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorJ. Uphill, J. Uphill MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Pal, S. Pal National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Hampson, S. Hampson National Prion Clinic, National Hospital for Neurology and Neurosurgery,Search for more papers by this authorJ. D. F. Wadsworth, J. D. F. Wadsworth MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorI. Dalmau Mena, I. Dalmau Mena MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorC. O'Malley, C. O'Malley MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Wroe, S. Wroe National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorA. Schapira, A. Schapira and University Department of Clinical Neurosciences, Royal Free & University College Medical School, London, UK.Search for more papers by this authorS. Brandner, S. Brandner MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorJ. Collinge, J. Collinge National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this author T. Webb, T. Webb National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Mead, S. Mead National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorJ. Beck, J. Beck MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorJ. Uphill, J. Uphill MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Pal, S. Pal National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Hampson, S. Hampson National Prion Clinic, National Hospital for Neurology and Neurosurgery,Search for more papers by this authorJ. D. F. Wadsworth, J. D. F. Wadsworth MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorI. Dalmau Mena, I. Dalmau Mena MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorC. O'Malley, C. O'Malley MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorS. Wroe, S. Wroe National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorA. Schapira, A. Schapira and University Department of Clinical Neurosciences, Royal Free & University College Medical School, London, UK.Search for more papers by this authorS. Brandner, S. Brandner MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this authorJ. Collinge, J. Collinge National Prion Clinic, National Hospital for Neurology and Neurosurgery, MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,Search for more papers by this author First published: 30 June 2009 https://doi.org/10.1111/j.1365-2990.2009.01012.xCitations: 10 Disclosure: J.C. is a Director, and J.C. and J.D.F.W. are shareholders and consultants of D-Gen Limited, an academic spin-out company working in the field of prion disease diagnosis, decontamination and therapeutics. D-Gen markets the ICSM18 antibody used in this study. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume35, Issue4August 2009Pages 427-432 RelatedInformation